Raptor Pharmaceuticals Fails Phase 2b Liver Study In Children, Falls 37%
September 14, 2015 at 19:40 PM EDT
Shares of Raptor Pharmaceuticals are down 37% after announcing failure of its phase 2b NASH study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.